ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Price & Overview
NASDAQ:ADVM • US00773U2078
Current stock price
The current stock price of ADVM is 4.36 USD. Today ADVM is up by 2.35%. In the past month the price increased by 0.93%. In the past year, price decreased by -18.81%.
ADVM Key Statistics
- Market Cap
- 96.269M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.58
- Dividend Yield
- N/A
ADVM Stock Performance
ADVM Stock Chart
ADVM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ADVM. When comparing the yearly performance of all stocks, ADVM is one of the better performing stocks in the market, outperforming 75.99% of all stocks.
ADVM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ADVM. ADVM may be in some trouble as it scores bad on both profitability and health.
ADVM Earnings
ADVM Forecast & Estimates
12 analysts have analysed ADVM and the average price target is 5 USD. This implies a price increase of 14.63% is expected in the next year compared to the current price of 4.36.
For the next year, analysts expect an EPS growth of -17.8% and a revenue growth 1166.67% for ADVM
ADVM Groups
Sector & Classification
ADVM Financial Highlights
Over the last trailing twelve months ADVM reported a non-GAAP Earnings per Share(EPS) of -8.58. The EPS decreased by -43.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.84% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADVM Ownership
ADVM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADVM
Company Profile
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 155 full-time employees. The company went IPO on 2014-07-31. The company discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Company Info
IPO: 2014-07-31
ADVERUM BIOTECHNOLOGIES INC
100 Cardinal Way
Redwood City CALIFORNIA 94063 US
CEO: Laurent Fischer
Employees: 155
Phone: 16506491004
ADVERUM BIOTECHNOLOGIES INC / ADVM FAQ
What does ADVM do?
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 155 full-time employees. The company went IPO on 2014-07-31. The company discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Can you provide the latest stock price for ADVERUM BIOTECHNOLOGIES INC?
The current stock price of ADVM is 4.36 USD. The price increased by 2.35% in the last trading session.
Does ADVERUM BIOTECHNOLOGIES INC pay dividends?
ADVM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADVM stock?
ADVM has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in ADVERUM BIOTECHNOLOGIES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADVM.
What is ADVERUM BIOTECHNOLOGIES INC worth?
ADVERUM BIOTECHNOLOGIES INC (ADVM) has a market capitalization of 96.27M USD. This makes ADVM a Micro Cap stock.